We are live on ! Find out more
PHAR

Pharming Group
PHAR

4 hedge funds and large institutions have $184K invested in Pharming Group in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

11% more capital invested

Capital invested by funds: $166K → $184K (+$18K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CPA
Cowen Prime Advisors
New York
+$9.31K
2
Wells Fargo
Wells Fargo
California
+$8.64K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$585
Name Holding Trade Value Shares
Change 		Change in
Stake
CPA
1
Cowen Prime Advisors
New York
$142K +$9.31K +1,050 +7%
Morgan Stanley
2
Morgan Stanley
New York
$22K – – –
UBS Group
3
UBS Group
Switzerland
$11K -$585 -66 -5%
Wells Fargo
4
Wells Fargo
California
$9K +$8.64K +974 New

PHAR Hedge Fund Activity: Q1 2022 in Review

4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q1 2022, worth a combined $184K — up 11% from $166K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PHAR positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Cowen Prime Advisors, adding an estimated $9.31K. The largest seller was UBS Group, cutting an estimated $585.

  • 4 institutional investors held Pharming Group (PHAR) as of Q1 2022, up from 3 in Q4 2021.
  • Funds reported $184K of Pharming Group stock for Q1 2022, up 11% quarter-over-quarter.
  • 1 fund opened new Pharming Group positions in Q1 2022 and 0 closed out, a net change of +1 holder.
  • The largest Pharming Group buyer in Q1 2022 was Cowen Prime Advisors, an estimated $9.31K added.
  • The largest Pharming Group seller in Q1 2022 was UBS Group, an estimated $585 sold.

Based on aggregated 13F filings for Q1 2022.